identify

Key trends and innovations in iGaming in 2024

In 2024, the gambling industry is entering a new era, keeping pace with technological advancements and consumers' changing tastes. This industry is constantly changing, and the latest trends and innovations play an important role in predicting its future. In this article, we will look at the main trends and innovative changes in the gambling industry in 2024. Toto site recommendation ranking Use of artificial intelligence and machine learning The use of artificial intelligence (AI) and machine learning in the gambling industry has made remarkable progress. These technologies play a key

Key trends and innovation in iGaming in 2024

In 2024, the gambling industry is entering a new era, keeping pace with technological advancements and consumers' changing tastes. This industry is constantly changing, and the latest trends and innovations play an important role in predicting its future. In this article, we will look at the main trends and innovative changes in the gambling industry in 2024. Use of artificial intelligence and machine learning The use of artificial intelligence (AI) and machine learning in the gambling industry has made remarkable progress. These technologies play a key role in keeping games

Koat.ai and Plato AI Announce Strategic Partnership to Revolutionize Data Intelligence and Drive Innovation.

New York, USA November 9, 2023.  Koat.ai, a next-generation social listening and intelligence platform, and Plato AI, a pioneer in open intelligence solutions, announced today a strategic partnership aimed at transforming the landscape of data intelligence and innovation. At the forefront of data intelligence, Koat.ai is a comprehensive and actionable market insights platform powered by AI. The company's proprietary manipulation detection technology enables it to identify both human and manipulated (inorganic) accounts, providing unparalleled clarity of insight and data. With granular sentiment analysis, quantified emotions, and real-time abnormality alerts, Koat.ai

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

Revolutionizing Clinical Trials: The Digital Watermarking and AI Duo

Revolutionizing Clinical Trials: The Digital Watermarking and AI Duo Clinical trials, the linchpin of medical research, have long been riddled with inefficiencies, from patient recruitment bottlenecks to data management hurdles. As a technology and banking analyst, I've seen how digital solutions can overhaul entire sectors, offering improved productivity and streamlined processes. It's high time that clinical trials get a dose of such digital innovation, and there's a potent combination on the horizon: digital watermarking coupled with Artificial Intelligence (AI). At first glance, one might wonder: how can a technique often

The Tightrope of Regulation

In a significant move at the recent G20 meeting in India, the International Monetary Fund (IMF) and the Financial Stability Board (FSB) released a joint paper outlining a framework for the global regulation of cryptocurrencies. While the proposals mostly tread familiar territory, what’s new is their conviction in crypto’s unstoppable growth and success. A flurry of optimism greeted the G20’s endorsement of the report because it advocates that countries don’t ban crypto. Hidden in its text, however, are some worrying signs. For example, on the first page, they state, “Widespread

Do you know baccarat, the flower of online casino games?

Baccarat is one of the most popular card games in casinos, and involves comparing cards between the player and the banker (or dealer) to determine the winner. The rules of Baccarat are simple, but it is a game that can be enjoyed in a variety of ways. Baccarat first appeared in online casino games in the mid-1900s when the Internet became popular. It was limited in the beginning, but in the 2000s, improvements in computer graphics and Internet speeds made it possible to provide a more realistic gaming environment, which

Starbox Group’s StarboxAI – ViPro Module: Transforming Content Creation

Kuala Lumpur, Malaysia, Sept 5th, 2023 – Starbox Group Holdings Ltd. (Nasdaq: STBX), a dynamic player in cash rebates, digital advertising, and payment solutions, with a vision of leading in artificial intelligence (“AI”) solutions throughout Southeast Asia, is making waves with the launch of its groundbreaking StarboxAI - ViPro module. This innovative module introduces a text-to-video feature set to redefine content creation. The Text-to-Video feature within the StarboxAI - ViPro module is not just an addition; it's a revelation. It empowers content creators to seamlessly transmute textual instructions or scripts

Starbox Group Holdings Ltd. Announces First Half of Fiscal Year 2023 Financial Results

Revenue and Net Profit Increased with Technology Driven Services Revenue Accounted for Approximately 43.8% of its Revenue KUALA LUMPUR, Malaysia, August 29, 2023 / Plato / Amplifi. Starbox Group Holdings Ltd. (Nasdaq: STBX) ("Starbox" or "the Company”), a service provider of cash rebates, digital advertising, and payment solutions with a goal of becoming a comprehensive AI solutions provider within Southeast Asia, today announced its unaudited financial results for the six months ended March 31, 2023. Mr. Lee Choon Wooi, Chairman and Chief Executive Officer of Starbox, commented, “We are excited

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement

Livento Group, Inc. Announces Second Quarter Results with Revenue Growth of Over 90%, Including Significant Achievements and Updates

NEW YORK, NY / August 14, 2023 / NuGene International, Inc./Livento Group, Inc. (OTC Pink:NUGN), a dynamic leader specializing in the acquisition and development of companies with disruptive business models in film, content, and technology sectors, is pleased to announce revenue growth of 91.65% for the second quarter of 2023, compared to the same period in 2022. Financial Highlights: Revenue Growth:The second quarter ending June 30, 2023, saw revenues of $431,184, up from $224,986 in 2022. For the six-month period ending June 30, 2023, revenues grew from $680,202 to $922,651, a growth of